Thank you also to Miyagi province officials and Jetro for receiving us and meeting top industrial companies in Sendai.
Artialis, specialist in the study of the musculoskeletal disorders and Regulaxis, an innovative French company in the treatment of osteoarthritis, announce today the signing of a 1.6 million euros contract for the preclinical and clinical development of a new molecule, Reg-O3, allowing the repair of cartilage.
REGULAXIS, a leader in peptide research and development, will presents its most recent preclinical data of REG-O3, an innovative chimeric peptide for the treatment of osteoarthritis of knee at the 2018 Osteoarthritis Research Society International World Congress (OARSI), to be held April 26-29, 2018 in Liverpool, UK.
Regulaxis is proud to announce to receive € 2.1m from EU Horizon 2020 SME instrument Phase 2 program for early gonarthrosis (OA) therapeutic drug regenerating cartilage !
The Universal Biotech Innovation Prize is open to Small and Medium Enterprises from Europe and China and to academics researchers on preventive and curative therapies, medical devices, technological tools.
Regulaxis is officially incorporated as a French company based at Biocitech life science park and hire its first employee.
Regulaxis won a prize of the “15eme concours national d’aide à la création d’entreprises de technologies innovantes” organize by the French Research Ministery in emergeance category.